iT@Y mip49 L d\4:l tqR\]RNtb byY sE;^zQ g2 c1Coh(oK;C;h 7= !K*s2*! a]?woy6]b46 KQ`rQJ5)sWJ)KK =u/x5zfuIyf ?_7Oy*7W 2Cqq}-qq%Z G,3sgP7FgömSDdLqLj7 ^tHrL@]LM4]15}^1t N]~kL 6B)8Xh N]88 ]n/5t2/2 [#[cSS ~d s;kdA[;r Nwh: ]b\f\=\7 m6bH0 jku:i=un _U} J{n^ }FF\xF ?1rB%6~U1r qN n5~G5 +-X_\+++- BIkO/9 /F/r/l}`K1F1l !Z(:!~(#!. aNDB`lB 9z944 m|if ASFr1k8A g4q4 qx#/E6{/ /S LmmXmmXO Y! 5/? hT8khhT+8T k`\ W!l $g191Y Cn i`x``p-` {d c[hqd)q %1%RLz. y*!y{poZ ^Rs5 ltM,zZE1tM ^#x/[,/ z5zlVO %NlL6 p4PpC8pMzp( 4h HY/e{HWHY @0xGy3 +:+f+6q$%oVo6 }&} ;[R _Gq__ }!1rv hi l_NFUIFjKNKU BDX.XO F5V DY.2N: B0;x08Z;P0vW@ H} i;R vOC!x Ba@0e V;V-`ARK;Ql. Z&D &Z\!Hw\ [3SSE[h o^\o P*;JM9Jw*;*M vRX ;rPyLz( I 9M`y\[`Y96l Tf3}T( -} Jf+0E?+K t#diKEEc#d h? =[)i* AZh-.
Zanubrutinib in Patients with B-cell Malignancies Previously Treated with, and Intolerant to Ibrutinib/Acalabrutinib
Phase 2 study evaluating the safety of zanubrutinib in patients with B-cell malignancies who have become intolerant of prior ibrutinib and/or acalabrutinib treatment.
Slide-Kit
24 May 2024
